Glofitamab,Obinutuzumab,Tocilizumab
roche
[]
 isn t it just. bispecifics in mcl could have such a benefit for patients with the disease. just need to get the development right so they ll be licensed and reimbursed.
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.